Soluble Urokinase Receptor and Acute Kidney Injury

Soluble urokinase plasminogen activator receptor was measured in three patient cohorts at risk for acute kidney injury. Experimental models were used to assess suPAR as a therapeutic target. High suPAR levels were associated with acute kidney injury in both clinical and experimental settings.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 382; no. 5; pp. 416 - 426
Main Authors Hayek, Salim S, Leaf, David E, Samman Tahhan, Ayman, Raad, Mohamad, Sharma, Shreyak, Waikar, Sushrut S, Sever, Sanja, Camacho, Alex, Wang, Xuexiang, Dande, Ranadheer R, Ibrahim, Nasrien E, Baron, Rebecca M, Altintas, Mehmet M, Wei, Changli, Sheikh-Hamad, David, Pan, Jenny S.-C, Holliday, Michael W, Januzzi, James L, Weisbord, Steven D, Quyyumi, Arshed A, Reiser, Jochen
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 30.01.2020
Subjects
Acute Kidney Injury - blood
Acute Kidney Injury - etiology
Acute Kidney Injury - prevention & control
Age
Aged
Angiography
Animals
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Bioenergetics
Biomarkers - blood
Cardiac Surgical Procedures - adverse effects
Cardiovascular disease
Coronary Angiography - adverse effects
Critical Illness
Diabetes
Disease Models, Animal
Enrollments
Female
Heart
Heart failure
Heart surgery
Humans
Intensive Care Units
Kidney diseases
Kidney Tubules - cytology
Kidney Tubules - drug effects
Kidney Tubules - pathology
Male
Medical imaging
Mice
Mice, Transgenic
Middle Aged
Mitochondria
Monoclonal antibodies
Morbidity
Odds Ratio
Patients
Plasma levels
Podocytes - drug effects
Podocytes - metabolism
Postoperative Complications - blood
Postoperative Complications - etiology
Reactive oxygen species
Receptors, Urokinase Plasminogen Activator - blood
Risk Assessment - methods
Superoxide
Therapeutic applications
Transgenic animals
Transgenic mice
U-Plasminogen activator
Urokinase-Type Plasminogen Activator - antagonists & inhibitors
Urokinase-Type Plasminogen Activator - pharmacology
Variables
Online AccessGet full text

Cover

More Information
Summary:Soluble urokinase plasminogen activator receptor was measured in three patient cohorts at risk for acute kidney injury. Experimental models were used to assess suPAR as a therapeutic target. High suPAR levels were associated with acute kidney injury in both clinical and experimental settings.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1911481